Research Associate, Immuno-Oncology

Research Associate, Immuno-Oncology

Cellectis Inc.

New York, NY, United States

<!—
/* Font Definitions /
@font-face
{font-family:Arial;
panose-1:2 11 6 4 2 2 2 2 2 4;
mso-font-charset:0;
mso-generic-font-family:swiss;
mso-font-pitch:variable;
mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
{font-family:“Courier New”;
panose-1:2 7 3 9 2 2 5 2 4 4;
mso-font-charset:0;
mso-generic-font-family:roman;
mso-font-pitch:fixed;
mso-font-signature:-536859905 -1073711037 9 0 511 0;}
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;
mso-font-charset:2;
mso-generic-font-family:auto;
mso-font-pitch:variable;
mso-font-signature:0 268435456 0 0 -2147483648 0;}
@font-face
{font-family:“Cambria Math”;
panose-1:2 4 5 3 5 4 6 3 2 4;
mso-font-charset:0;
mso-generic-font-family:roman;
mso-font-pitch:variable;
mso-font-signature:-536870145 1107305727 0 0 415 0;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;
mso-font-charset:0;
mso-generic-font-family:swiss;
mso-font-pitch:variable;
mso-font-signature:-536870145 1073786111 1 0 415 0;}
/
Style Definitions /
p.MsoNormal, li.MsoNormal, div.MsoNormal
{mso-style-unhide:no;
mso-style-qformat:yes;
mso-style-parent:"";
margin-top:0cm;
margin-right:0cm;
margin-bottom:8.0pt;
margin-left:0cm;
line-height:107%;
mso-pagination:widow-orphan;
font-size:11.0pt;
font-family:“Calibri”,sans-serif;
mso-fareast-font-family:Calibri;
mso-bidi-font-family:“Times New Roman”;
mso-fareast-language:EN-US;}
p
{mso-style-priority:99;
mso-margin-top-alt:auto;
margin-right:0cm;
mso-margin-bottom-alt:auto;
margin-left:0cm;
mso-pagination:widow-orphan;
font-size:12.0pt;
font-family:“Times New Roman”,serif;
mso-fareast-font-family:“Times New Roman”;}
.MsoChpDefault
{mso-style-type:export-only;
mso-default-props:yes;
font-size:10.0pt;
mso-ansi-font-size:10.0pt;
mso-bidi-font-size:10.0pt;
font-family:“Calibri”,sans-serif;
mso-ascii-font-family:Calibri;
mso-fareast-font-family:Calibri;
mso-hansi-font-family:Calibri;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:70.85pt 70.85pt 70.85pt 70.85pt;
mso-header-margin:36.0pt;
mso-footer-margin:36.0pt;
mso-paper-source:0;}
div.WordSection1
{page:WordSection1;}
/
List Definitions */
@list l0
{mso-list-id:546914646;
mso-list-type:hybrid;
mso-list-template-ids:1957844252 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:45.0pt;
text-indent:-18.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:81.0pt;
text-indent:-18.0pt;
font-family:“Courier New”,serif;}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:117.0pt;
text-indent:-18.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:153.0pt;
text-indent:-18.0pt;
font-family:Symbol;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:189.0pt;
text-indent:-18.0pt;
font-family:“Courier New”,serif;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:225.0pt;
text-indent:-18.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:261.0pt;
text-indent:-18.0pt;
font-family:Symbol;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:297.0pt;
text-indent:-18.0pt;
font-family:“Courier New”,serif;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:none;
mso-level-number-position:left;
margin-left:333.0pt;
text-indent:-18.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:785007865;
mso-list-type:hybrid;
mso-list-template-ids:-1767606202 67698689 67698691 67698693 67698689 67698691 67698693 67698689 67698691 67698693;}
@list l1:level1
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:Symbol;}
@list l1:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:“Courier New”,serif;}
@list l1:level3
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:Wingdings;}
@list l1:level4
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:Symbol;}
@list l1:level5
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:“Courier New”,serif;}
@list l1:level6
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:Wingdings;}
@list l1:level7
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:Symbol;}
@list l1:level8
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:“Courier New”,serif;}
@list l1:level9
{mso-level-number-format:bullet;
mso-level-text:?;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
font-family:Wingdings;}
ol
{margin-bottom:0cm;}
ul
{margin-bottom:0cm;}
—>

Cellectis is a clinical-stage biopharmaceutical company focused on
developing a new generation of cancer immunotherapies based on gene-edited allogeneic
T-cells (UCART). By capitalizing on its 19 years of expertise in gene editing –
built on its flagship TALEN® technology and pioneering electroporation system
PulseAgile – Cellectis uses the power of the immune system to target and
eradicate cancer cells.

 

Using its life-science-focused, pioneering genome engineering technologies,
Cellectis’ goal is to create innovative products in multiple fields and with
various target markets.

Cellectis is listed on the
Nasdaq market (ticker: CLLS) and
on Euronext Growth (ticker:
ALCLS). To find out more about us, visit our website:
www.cellectis.com

 

Talking about gene editing? We do
it. TALEN® is a registered trademark owned by Cellectis.

 

Job summary.

 

Our Immuno-Oncology (IO) division
is seeking a highly dynamic and self-driven Research Associate to join the team.
Succesful candidates will  perform
diverse in vivo and in vitro methodologies to develop
innovative cellular therapies. Ideal candidates are preferably skilled in the
following techniques: flow cytometry, cell culture (cell lines and primary
cultures), cell-based and immunological assays, lentiviral transduction and
mouse handling. Candidates should be able to perform data analysis with minimal
supervision and keep detailed documentation. Succesful candidates thrive in a
fast-moving, goal-oriented environment aiming to make a change in cancer
therapy.

 

The
successful candidate will:

 

·     
Work with
scientists to develop the next generation of adoptive cell therapies.

·     
Design,
perform, analyze and troubleshoot experiments independently.

·     
Maintain cell
cultures and conduct cell-based and immunological assays.

·     
Perform and
analyze multicolor flow cytometry experiments.

·     
Preferably
participate in in vivo murine-based
studies.

·     
Keep careful
documentation and present data to a multidisciplinary team.

·     
Participate to
ensure smooth day-to-day operation of the laboratory.

 

Qualifications
and Education Requirements

 

·      BS/MS in Biology,
Immunology, or related discipline with 1+ years experience.

·      Experience in
T-cell and CAR-T cell methodologies is highly desired.

·    Strong
expertise in cellular biology techniques (cell culture, viral transduction, transfection) and cell-based and immunological assays (ELISA, cytotoxicity).

·     Solid hands on
experience in multicolor flow cytometry and analysis.

·     Expertise with
murine models (injections,  general
surgical procedures).

·    Hands on
expertise on molecular biology and gene editing techniques is a plus.

·   Experience in
Office (Word, PowerPoint, Excel) and data analysis tools (Flowjo, prism).

·   Ability to
meticulously maintain an electronic lab notebook (ELN), document laboratory information
management system (LIMS) and drafting SOPs.

· Excellent
organizational skills and multitasking proficiency in a fast-paced environment.

·   Be a team
player and efficiently work independently

 

How to Apply

 

Applicants should send their CV, a description of their research experience
and interest to
CLI_RIO_2019-02@cellectis.com

 

Favorite

Apply with CV and Cover Letter

Fields with a * are mandatory
Must be a .doc, .docx, or .pdf file and no larger than 1MBMust be a .doc, .docx, or .pdf file and no larger than 1MB
Position

Research Associate, Immuno-Oncology